Oбщaя зaбoлeвaeмocть вceгo нaceлeния Poccии в 2012 гoдy. Cтaтиcтичecкиe мaтepиaлы, Чacть II 2013. [The general prevalences of diseases in the total population of Russia in 2012. Statistical Materials, Part II 2013 (In Russian)]. http://www.rosminzdrav.ru/documents/8029-statisticheskaya-informatsiya-2012. Accessed 19 Oct 2018.
Зaбoлeвaeмocть вceгo нaceлeния Poccии в 2014 гoдy. Cтaтиcтичecкиe мaтepиaлы, Чacть II 2015 [The prevalences of diseases in the total population of Russia in 2014. Statistical Materials, Part II 2015 (In Russian)]. https://www.rosminzdrav.ru/documents/9479-statisticheskaya-informatsiya-za-2014. Accessed 19 Oct 2018.
Зaбoлeвaeмocть вceгo нaceлeния Poccии в 2016 гoдy. Cтaтиcтичecкиe мaтepиaлы Чacть II 2017. [The prevalences of diseases in the total population of Russia in 2016. Statistical Materials, Part II 2017 (In Russian)]. https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisticheskiy-sbornik-2016-god. Accessed 19 Oct 2018.
Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study. BMJ. 2011;343:d4656.
Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. J Thromb Haemost. 2000;83(5):657–60.
Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692–9.
Van Beek E, Buller H, Ten Cate J. Epidemiology of venous thromboembolism. A textbook of vascular medicine. London: Arnold; 1996. p. 471–88.
Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158(6):585–93.
Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125(1):1–7.
Mohr DN, Silverstein MD, Heit JA, Petterson TM, O’fallon WM, Melton LJ. The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study. Mayo Clin Proc. 2000;75(12):1249–56.
Franzeck UK, Schalch I, Jäger KA, Schneider E, Grimm J, Bollinger A. Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk patients (Zürich study). Circulation. 1996;93(1):74–9.
Beyth RJ, Cohen AM, Landefeld CS. Long-term outcomes of deep-vein thrombosis. Arch Intern Med. 1995;155(10):1031–7.
Kahn S, Comerota A, Cushman M. Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014;130(18):1636–61.
Prandoni P, Frulla M, Sartor D, Concolato A, Girolami A. Vein abnormalities and the post-thrombotic syndrome. J Thromb Haemost. 2005;3(2):401–2.
Vedovetto V, Dalla Valle F, Milan M, Pesavento R, Prandoni P. Residual vein thrombosis and trans-popliteal reflux in patients with and without the post-thrombotic syndrome. Thromb Haemost. 2013;110(4):854–5.
Galanaud J, Holcroft C, Rodger M, et al. Predictors of post-thrombotic syndrome in a population with a first deep vein thrombosis and no primary venous insufficiency. J Thromb Haemost. 2013;11(3):474–80.
Tick L, Kramer M, Rosendaal F, Faber W, Doggen C. Risk factors for post-thrombotic syndrome in patients with a first deep venous thrombosis. J Thromb Haemost. 2008;6(12):2075–81.
Comerota AJ, Grewal N, Martinez JT, et al. Postthrombotic morbidity correlates with residual thrombus following catheter-directed thrombolysis for iliofemoral deep vein thrombosis. J Vasc Surg. 2012;55(3):768–73.
Budnik I, Brill A. Immune factors in deep vein thrombosis initiation. Trends Immunol. 2018;39:610–23.
Henke PK, Wakefield T. Thrombus resolution and vein wall injury: dependence on chemokines and leukocytes. Thromb Res. 2009;123:S72–8.
Rabinovich A, Cohen JM, Cushman M, et al. Inflammation markers and the risk of post thrombotic syndrome: results from the Bio-Sox Study. Blood. 2013;122(21):36.
Rabinovich A, Cohen JM, Cushman M, et al. Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2015;3(4):347–53.
Roumen-Klappe E, Janssen M, Van Rossum J, et al. Inflammation in deep vein thrombosis and the development of post-thrombotic syndrome: a prospective study. J Thromb Haemost. 2009;7(4):582–7.
Shbaklo H, Holcroft CA, Kahn SR. Levels of inflammatory markers and the development of the post-thrombotic syndrome. J Thromb Haemost. 2009;101(03):505–12.
Bouman A, Smits J, Ten Cate H, Ten Cate-Hoek A. Markers of coagulation, fibrinolysis and inflammation in relation to post-thrombotic syndrome. J Thromb Haemost. 2012;10(8):1532–8.
Korthuis RJ, Gute DC. Adhesion molecule expression in postischemic microvascular dysfunction: activity of a micronized purified flavonoid fraction. J Vasc Res. 1999;36(Suppl 1):15–23.
Takase S, Lerond L, Bergan JJ, Schmid-Schonbein GW. The inflammatory reaction during venous hypertension in the rat. Microcirculation. 2000;7(1):41–52.
Takase S, Pascarella L, Lerond L, Bergan JJ, Schmid-Schonbein GW. Venous hypertension, inflammation and valve remodeling. Eur J Vasc Endovasc Surg. 2004;28(5):484–93.
Maria das Graças C, Cyrino FZ, de Carvalho JJ, Blanc-Guillemaud V, Bouskela E. Protective effects of micronized purified flavonoid fraction (MPFF) on a novel experimental model of chronic venous hypertension. Eur J Vasc Endovasc Surg. 2018;55(5):694–702.
Shoab SS, Porter JB, Scurr JH, Coleridge-Smith PD. Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: a pilot study. J Vasc Surg. 2000;31(3):456–61.
Bogachev VY, Boldin BV, Lobanov VN. Benefits of micronized purified flavonoid fraction as adjuvant therapy on inflammatory response after sclerotherapy. Int Angiol. 2018;37(1):71–8.
Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Eng J Med. 2003;349(13):1227–35.
Vasquez MA, Munschauer CE. Venous Clinical Severity Score and quality-of-life assessment tools: application to vein practice. Phlebology. 2008:259–75.
CIVIQ users’ guide. http://www.civiq-20.com. Accessed 19 Oct 2018.
Villalta S, Bagatella P, Piccioli A, Lensing A, Prins M, Prandoni P. Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome [abstract]. Haemostasis. 1994(24 suppl 1):158a.
Marder VJ, Soulen RL, Atichartakarn V, et al. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med. 1977;89(5):1018–29.
Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4.
Henke PK, Wakefield TW, Diaz JA. Acute and chronic venous thrombosis: pathogenesis and new insights. Handbook of venous and lymphatic disorders. Boca Raton: CRC; 2017. p. 121–36.
Meissner MH, Caps MT, Bergelin RO, Manzo RA, Strandness DE Jr. Propagation, rethrombosis and new thrombus formation after acute deep venous thrombosis. J Vasc Surg. 1995;22(5):558–67.
Egermayer P. The effects of heparin and oral anticoagulants on thrombus propagation and prevention of the postphlebitic syndrome: a critical review of the literature. Prog Cardiovasc Dis. 2001;44(1):69–80.
Hull RD, Liang J, Townshend G. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med. 2011;124(8):756–65.
Poredos P, Jezovnik M. Heparin promotes recanalization of venous thrombotic occlusions. Int Angiol. 2018;37(4):261–8.
Roussin A. Effective management of acute deep vein thrombosis: direct oral anticoagulants. Int Angiol. 2015;34(1):16–29.
Utne K, Dahm A, Wik H, Jelsness-Jørgensen L, Sandset P, Ghanima W. Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome. Thromb Res. 2018;163:6–11.
Jeraj L, Jezovnik M, Poredos P. Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome. Thromb Res. 2017;157:46–8.
Prandoni P, Ageno W, Mumoli N, et al. Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants. Thromb Res. 2017;153:97–100.
Rothmeier AS, Ruf W. Protease-activated receptor 2 signaling in inflammation. Semin Immunopathol. 2012;34(1):133–4.
Ramacciotti E, Volpiani GG, Davila R, Resende VA, Silveira FM, Fareed J. Early recanalization of veins in patients with DVT treated with rivaroxaban: do we need to move from bedside to bench again? Int Angiol. 2018;37(1):1–3.
Piovella F, Crippa L, Barone M, et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica. 2002;87(5):515–22.
Siragusa S, Malato A, Anastasio R, et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood. 2008;112(3):511–5.
Prandoni P, Lensing AW, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med. 2002;137(12):955–60.
Prandoni P, Prins MH, Lensing AW, et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med. 2009;150(9):577–85.
Trinh F, Paolini D, Fish J, Kasper G, Lurie F. Use of Villalta score for defining post-thrombotic disease may lead to false-positive diagnosis in 42% of patients with primary chronic venous disease. J Vasc Surg Venous Lymphat Disord. 2018;6(2):291.
Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol. 2018;37(2):143–54.